Table 3. Comparison of common adverse events.
| AEs | TCbHP group (n=46) | THP group (n=26) | P value | |||||
|---|---|---|---|---|---|---|---|---|
| All grades | Grade ≥3 | All grades | Grade ≥3 | All grades | Grade ≥3 | |||
| Neutropenia | 31 (67%) | 8 (17%) | 15 (58%) | 3 (12%) | 0.451 | 0.735 | ||
| Anaemia | 21 (46%) | 6 (13%) | 6 (23%) | 0 | 0.077 | 0.081 | ||
| Thrombocytopenia | 19 (41%) | 8 (17%) | 3 (12%) | 0 | 0.009 | 0.044 | ||
| Nausea | 30 (65%) | 3 (7%) | 15 (58%) | 1 (4%) | 0.615 | 1.0 | ||
| Vomiting | 21 (46%) | 3 (7%) | 9 (35%) | 1 (4%) | 0.458 | 1.0 | ||
| Diarrhea | 25 (54%) | 7 (15%) | 8 (31%) | 0 | 0.084 | 0.044 | ||
| Alanine aminotransferase increased | 9 (20%) | 2 (4%) | 3 (12%) | 0 | 0.517 | 0.532 | ||
| Rash | 6 (13%) | 0 | 2 (8%) | 0 | 0.702 | NA | ||
| Musculoskeletal pain | 12 (26%) | 0 | 3 (12%) | 0 | 0.227 | NA | ||
| Peripheral sensory neuropathy | 14 (30%) | 0 | 8 (31%) | 0 | 1.0 | NA | ||
| Significant LVEF decline events (≥10 percentage points from baseline and to <50%) | 0 | NA | 1 (4%) | NA | 0.361 | NA | ||
| Carboplatin dose reduction | 17 (37%) | NA | NA | NA | ||||
| Carboplatin discontinuation | 6 (13%) | NA | NA | NA | ||||
| Docetaxel dose reduction | 0 | NA | 3 (12%) | NA | ||||
| Docetaxel discontinuation | 0 | NA | 0 | NA | ||||
AEs, adverse events; LVEF, left ventricular ejection fraction; NA, no available.